Publications by authors named "L D'Hooghe"
Article Synopsis
- Rozanolixizumab (UCB7665) is a monoclonal antibody designed to target and reduce harmful IgG antibodies in autoimmune and alloimmune diseases by inhibiting the neonatal Fc receptor (FcRn).
- Studies show that this antibody effectively lowers plasma IgG levels in animal models (mice and cynomolgus monkeys) without affecting albumin levels and demonstrates a good safety profile during prolonged administration.
- Current research includes clinical trials for conditions like immune thrombocytopenia and myasthenia gravis, suggesting rozanolixizumab could be a promising new treatment option for these diseases.
A major role for FcRn is the salvage of pinocytosed IgG and albumin from a degradative fate in lysosomes. FcRn achieves this by binding IgG in a pH-dependent manner in acidic endosomes and recycling it to the plasma membrane to be released at neutral pH. This is important in maintaining high serum IgG and albumin levels and has the potential to be exploited to modulate the pharmacokinetics of antibody-based therapeutics.
View Article and Find Full Text PDF